Proton pump inhibitor in the prevention of upper gastrointestinal mucosal injury associated with dual antiplatelet therapy after coronary artery bypass grafting (DACAB-GI-2): study protocol for a randomized controlled trial

Yunpeng Zhu, Xiaojin Wang, Yi Yang, Lei Liu, Qiang Zhao, Lifen Yu, Yunpeng Zhu, Xiaojin Wang, Yi Yang, Lei Liu, Qiang Zhao, Lifen Yu

Abstract

Background: Dual antiplatelet therapy (DAPT) is recommended in secondary prevention after coronary artery bypass grafting (CABG), but it is inevitably associated with the risk of bleeding, of which gastrointestinal bleeding accounts for more than half. Proton pump inhibitors (PPIs) may increase the risk of major cardiovascular adverse events when reducing the risk of upper gastrointestinal bleeding. Therefore, the optimal duration of a PPI in combination with DAPT is unclear.

Methods: The "Proton Pump Inhibitor Preventing Upper Gastrointestinal Injury in Patients on Dual Antiplatelet Therapy after CABG" (DACAB-GI-2) study is a prospective, single-center, open-label, parallel, randomized controlled trial. A total of 232 eligible subjects who are scheduled or initiated on DAPT (clopidogrel plus aspirin or ticagrelor plus aspirin) for 12 months immediately after CABG will be enrolled and be randomized in a 1:1 ratio to either a 12-month pantoprazole treatment arm or a 1-month treatment arm. The primary outcome is to assess the rate of gastroduodenal erosions and ulcers evaluated by esophagogastroduodenoscopy (EGD) within 12 months after randomization, based on the modified Lanza score. Secondary outcomes include reflux esophagitis and upper gastrointestinal bleeding. Other pre-specified outcomes include major adverse cardiovascular events, graft failure, and all-cause death.

Discussion: This study aims to compare the efficacy and safety of 12 months and 1 month of pantoprazole treatment in preventing DAPT-related upper gastrointestinal mucosal injury after CABG.

Trial registration: ClinicalTrials.gov NCT03908593 .

Keywords: Coronary artery bypass grafting; Dual antiplatelet therapy; Gastrointestinal mucosal injury; Proton pump inhibitor.

Conflict of interest statement

Dr. Yu reported receiving grant funding, personal fees, and nonfinancial support from Takeda (China) International Trading Co., Ltd. The other authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Trial flow diagram
Fig. 2
Fig. 2
Schedule of enrollment, interventions, and assessments for the trial

References

    1. Kulik A, Ruel M, Jneid H, Ferguson TB, Hiratzka LF, Ikonomidis JS, et al. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. Circulation. 2015;131:927–964. doi: 10.1161/CIR.0000000000000182.
    1. Koskinas KC, Räber L, Zanchin T, Wenaweser P, Stortecky S, Moschovitis A, et al. Clinical impact of gastrointestinal bleeding in patients undergoing percutaneous coronary interventions. Circ Cardiovasc Interv. 2015;8.
    1. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008;118:1894–1909. doi: 10.1161/CIRCULATIONAHA.108.191087.
    1. Moukarbel GV, Bhatt DL. Antiplatelet therapy and proton pump inhibition: clinician update. Circulation. 2012;125:375–380. doi: 10.1161/CIRCULATIONAHA.111.019745.
    1. Chinese Expert Consensus Group on the Prevention and Treatment of Digestive Tract Injury with Antiplatelet Drugs. Chinese expert consensus on the prevention and treatment of gastrointestinal injury by antiplatelet drugs (2012 update). Chinese Journal of Internal Medicine. 2013;52:264-270.
    1. Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821–827. doi: 10.1124/dmd.32.8.821.
    1. El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018;14:447–460. doi: 10.1080/17425255.2018.1461835.
    1. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J. 2018;39:213–260. doi: 10.1093/eurheartj/ehx419.
    1. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68:1082–1115. doi: 10.1016/j.jacc.2016.03.513.
    1. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057. doi: 10.1056/NEJMoa0904327.
    1. Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol. 2010;56:1456–1462. doi: 10.1016/j.jacc.2010.03.100.
    1. Tang C, Zhu Y, Yang X, Xu B, Ye C, Yang Y, et al. Upper gastrointestinal mucosal injury associated with ticagrelor plus aspirin, ticagrelor alone, or aspirin alone at 1-year after coronary artery bypass grafting. J Gastroenterol Hepatol. 2020;35:1720–1730. doi: 10.1111/jgh.15030.
    1. Nam SJ, Lee HS, Lim YJ. Evaluation of gastric disease with capsule endoscopy. Clin Endosc. 2018;51:323–328. doi: 10.5946/ce.2018.092.
    1. Weledji EP. Acute upper gastrointestinal bleeding: a review. Surg Pract Sci. 2020;1:100004. doi: 10.1016/j.sipas.2020.100004.
    1. Oakland K, Chadwick G, East JE, Guy R, Humphries A, Jairath V, et al. Diagnosis and management of acute lower gastrointestinal bleeding: guidelines from the British Society of Gastroenterology. Gut. 2019;68:776–789. doi: 10.1136/gutjnl-2018-317807.
    1. Asge Standards of Practice Committee. Muthusamy VR, Lightdale JR, Acosta RD, Chandrasekhara V, Chathadi KV, et al. The role of endoscopy in the management of GERD. Gastrointest Endosc. 2015;81:1305–1310. doi: 10.1016/j.gie.2015.02.021.
    1. Park J, Cho YK, Kim JH. Current and future use of esophageal capsule endoscopy. Clin Endosc. 2018;51:317–322. doi: 10.5946/ce.2018.101.
    1. Lanza FL, Marathi UK, Anand BS, Lichtenberger LM. Clinical trial: comparison of ibuprofen-phosphatidylcholine and ibuprofen on the gastrointestinal safety and analgesic efficacy in osteoarthritic patients. Aliment Pharmacol Ther. 2008;28:431–442. doi: 10.1111/j.1365-2036.2008.03765.x.
    1. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol. 1996;28:616–626. doi: 10.1016/0735-1097(96)00206-9.
    1. Zhao Q, Zhu Y, Xu Z, Cheng Z, Mei J, Chen X, et al. Effect of ticagrelor plus aspirin, ticagrelor alone, or aspirin alone on saphenous vein graft patency 1 year after coronary artery bypass grafting: a randomized clinical trial. JAMA. 2018;319:1677–1686. doi: 10.1001/jama.2018.3197.
    1. Chan FKL, Goh KL, Reddy N, Fujimoto K, Ho KY, Hokimoto S, et al. Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines. Gut. 2018;67:405–417. doi: 10.1136/gutjnl-2017-315131.
    1. Han Y, Liao Z, Li Y, Zhao X, Ma S, Bao D, et al. Magnetically controlled capsule endoscopy for assessment of antiplatelet therapy-induced gastrointestinal injury. J Am Coll Cardiol. 2022;79:116–128. doi: 10.1016/j.jacc.2021.10.028.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir